Analytics 4 Life® and Actelion Enter Research Agreement to Develop New Diagnostics for Pulmonary Hypertension
Research endeavor marks a clinical research expansion of the CorVista® platform
RESEARCH TRIANGLE PARK, NC and TORONTO, ON, December 11, 2018 — Analytics 4 Life, a digital health company dedicated to improving existing diagnostic pathways, and Actelion Pharmaceuticals Ltd., today announced a collaborative agreement to investigate the use of Analytics 4 Life’s diagnostic imaging technology in pulmonary hypertension. The first 500-person clinical study has been initiated for this serious, life-threatening condition affecting millions of people worldwide.
Analytics 4 Life seeks to use innovative machine learning technologies to develop a more complete picture of cardiac health with a single, non-invasive test. “Today marks a significant milestone for the company as we embark on a new disease state to study,” said Don Crawford, chief executive officer, Analytics 4 Life. “We look forward to collaborating with Actelion to expand research of our CorVista platform into pulmonary hypertension.”
Actelion, a Janssen Pharmaceutical company of Johnson & Johnson, is a leader in the science and treatment of pulmonary arterial hypertension (PAH), a type of pulmonary hypertension – a cardiovascular disorder with an average life expectancy of only seven to nine years once diagnosed and therapy is initiated. On average, there is a three-year delay from a patient presenting with symptoms to receiving an accurate diagnosis of PAH from right heart catheterization. The goal of this collaboration is to diagnose more patients with all types of pulmonary hypertension earlier, leading to improved outcomes.
Analytics 4 Life is a resident company at Johnson & Johnson Innovation, JLABS @ Toronto. “As a resident in the space, we have benefited from a rich ecosystem of cardiovascular medical device development and expertise,” said Shyam Ramchandani, Ph.D., vice president, research, Analytics 4 Life. “We clearly see how our machine learning work in coronary artery disease can be leveraged in pulmonary hypertension. This new research expansion exemplifies the growth of Analytics 4 Life, as well as the advancements in healthcare solutions being fostered at Johnson & Johnson Innovation, JLABS.”
This evening, Johnson & Johnson Innovation, JLABS and Actelion are bringing together pulmonary hypertension experts for their Science 1st Series: The Future Treatment of Pulmonary Arterial Hypertension hosted at JLABS @ Toronto.
CorVista operates on a secure, cloud-based platform amenable to clinical investigation for a myriad of cardiovascular diseases. Paired physiologic signals and clinical results from gold standard tests are collected and wirelessly transmitted to the cloud, where machine learning analysis can be performed to develop clinically relevant algorithms that can ultimately be embedded into the CorVista system. It has already been tested in over 2,600 patients in the Coronary Artery Disease Learning and Algorithm Development (CADLAD) clinical study.
About Pulmonary Hypertension
Pulmonary hypertension (PH) is a progressive disease where blood pressure in the pulmonary vasculature increases leading to eventual right heart failure and death. PH affects roughly 25 million people worldwide and is classified into five groups based on etiology, one of which is PAH. There is currently no cure for some types of PH, including PAH, but early diagnosis and treatment can relieve symptoms and slow disease progression.
About CorVista® System
CorVista is a non-invasive medical imaging system that is designed to acquire and process patient data and display results in a report accessible via a secure web portal. The system scans signals emitted by the body without radiation, exercise, or pharmacologic stress and wirelessly transmits the signal package to the cloud for processing and report generation. Physicians can interpret and use the results as part of an assessment of their patient. CorVista is an investigational device limited by federal law to investigational use. CorVista is not available for commercial distribution.
About Analytics 4 Life®
Analytics 4 Life is pioneering digital health using artificial intelligence to develop a completely new cardiac diagnostic modality. With an initial focus on coronary artery disease, heart failure, and pulmonary hypertension, Analytics 4 Life is advancing a novel, radiation-free, and exercise-free cardiac diagnostic platform aimed at improving existing care pathways. Analytics 4 Life is based in Toronto with U.S. headquarters in Washington, D.C.
Chris Bing Ernst
SOURCE: Business Wire